The company
Revolution Medicines, Inc.
RVMD · Nasdaq
Health CareBiotechnologyLeading
RVMD stood above a rising 150-day average in 52 of the last 52 weekly readings, every one of them. It is 10.0% above that average now. Biotechnology: 18% of its 561 stocks in an uptrend (−9 points in four weeks); Health Care: 28% (−6 points in four weeks).
Statistics
- Rotation
- Leading
- Weeks in an uptrend
- 52 in a row
- Industry in uptrend
- 18% -9 in 4 wk
- Insider buys, 12 months
- $0
- Insider sales, 12 months
- $292.4M
- Officials’ trades on record
- 6
- Institutions holding
- 659 (+179)
In the rotation
Each square a week: lit when it closed above a rising 150-day average. 52 of 52 weeks.
23 Apr – 22 Oct
Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has been slipping.
Money in and out
1 Nov 2024 – 1 Oct 2026
Open-market buys above the line and sales below, in dollars.
Congress and officials
6 disclosed lines: House 0, Senate 0, executive 6; 3 people.
| Who | Did | Amount | Traded |
|---|---|---|---|
| Scott A. Kupor Executive branch: Office of Government EthicsOffice of Personnel Management | sold | $1k–$15k | 30 Jul 2026filed 30 Sep 2026 |
| Donald J. Trump Executive branch: Office of Government EthicsWhite House Office | bought | $1k–$15k | 17 Jul 2026filed 22 Sep 2026 |
| Donald J. Trump Executive branch: Office of Government EthicsWhite House Office | bought | $1k–$15k | 15 Jun 2026filed 22 Aug 2026 |
| Donald J. Trump Executive branch: Office of Government EthicsWhite House Office | sold | $50k–$100k | 18 May 2026filed 1 Jul 2026 |
| Donald J. Trump Executive branch: Office of Government EthicsWhite House Office | bought | $1k–$15k | 23 Mar 2026filed 14 May 2026 |
| Eric S. Lander Executive branch: Office of Government EthicsOffice of Science and Technology Policy | sold | $100k–$250k | 10 Jun 2021filed 8 Sep 2021 |
Insiders
Buy orders, 12 months0
Sale orders, 12 months57
Buyers · sellers0 · 12
| Who | Did | Shares | Traded |
|---|---|---|---|
| Alan B. SandlerChief Development Officer | sold | 2,200at $200.82 | 29 Sep 2026filed 1 Oct 2026 |
| Alan B. SandlerChief Development Officer | sold | 1,609at $201.72 | 29 Sep 2026filed 1 Oct 2026 |
| Alan B. SandlerChief Development Officer | sold | 1,000at $202.81 | 29 Sep 2026filed 1 Oct 2026 |
| Alan B. SandlerChief Development Officer | sold | 1,199at $203.91 | 29 Sep 2026filed 1 Oct 2026 |
| Alan B. SandlerChief Development Officer | sold | 301at $204.72 | 29 Sep 2026filed 1 Oct 2026 |
| Jeff CisliniSVP & General Counsel | sold | 765at $207.32 | 25 Sep 2026filed 29 Sep 2026 |
| Anthony ManciniOfficer | sold | 3,121at $200.54 | 25 Sep 2026filed 28 Sep 2026 |
| Anthony ManciniOfficer | sold | 587at $200.00 | 24 Sep 2026filed 28 Sep 2026 |
| Elizabeth M. AndersonDirector | sold | 910at $191.85 | 22 Sep 2026filed 24 Sep 2026 |
| Elizabeth M. AndersonDirector | sold | 4,985at $192.54 | 22 Sep 2026filed 24 Sep 2026 |
| Elizabeth M. AndersonDirector | sold | 2,648at $193.44 | 22 Sep 2026filed 24 Sep 2026 |
| Elizabeth M. AndersonDirector | sold | 1,500at $194.59 | 22 Sep 2026filed 24 Sep 2026 |
Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.
Institutions
Holders659+179 on the quarter
New · exited238 · 59
Reported value$39.5B
Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.
| Manager | Shares | Change |
|---|---|---|
| BlackRock, Inc.added · filed 7 Aug 2026 | 13,695,790$2.6B | +2,483,084+22.1% |
| FARALLON CAPITAL MANAGEMENT, L.L.C.reduced · filed 14 Aug 2026 | 13,550,796$2.5B | -54,000−0.4% |
| FMR LLCadded · filed 13 Aug 2026 | 12,200,422$2.3B | +3,736,108+44.1% |
| BAKER BROS. ADVISORS LPadded · filed 14 Aug 2026 | 11,443,357$2.1B | +1,888,000+19.8% |
| Jupiter Topco LLCnew · filed 14 Aug 2026 | 10,736,145$2.0B | +10,736,145 |
| Darwin Global Management, Ltd.added · filed 14 Aug 2026 | 10,629,822$2.0B | +8,418,804+380.8% |
| VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026 | 9,088,661$1.7B | +726,377+8.7% |
| VANGUARD PORTFOLIO MANAGEMENT LLCadded · filed 13 Aug 2026 | 8,294,855$1.6B | +792,232+10.6% |
| Nextech Invest Ltd.unchanged · filed 14 Aug 2026 | 7,601,087$1.4B | 00.0% |
| Paradigm Biocapital Advisors LPreduced · filed 14 Aug 2026 | 6,361,323$1.2B | -294,380−4.4% |
31 Mar 2023 – 30 Jun 2026
News
Revolution Medicines Presents Overall Survival Data for RASONQUE™ (daraxonrasib) Across Subgroups in Previously Treated Metastatic Pancreatic Cancer at ESMO 2026manilatimes.net · 23 Oct 2026Revolution Medicines (RVMD) Has an Approved Cancer Drug. Can Its $38 Billion Valuation Deliver?insidermonkey.com · 20 Oct 2026Revolution Medicines Begins Phase 3 Trial Of Three-Drug Lung Cancer Regimen; Stock Uprttnews.com · 20 Oct 2026Revolution Medicines' Pancreatic Cancer Drug Gets Positive EU Reviewfinanzen.ch · 15 Oct 2026Revolution Medicines' Pancreatic Cancer Drug Gets Positive EU Reviewrttnews.com · 15 Oct 2026Revolution Medicines' RASONQUE(™) (daraxonrasib) Receives Positive CHMP Opinion Recommending Marketing Authorization in European Union for Metastatic Pancreatic Cancermanilatimes.net · 15 Oct 2026Propanc Biopharma Reports Data Showing 90% Tumor Growth Inhibition with PRP in Pancreatic Cancer Models, Contrasting Profile with Revolution Medicines' Daraxonrasibmanilatimes.net · 7 Oct 2026Is Buying Royalty Pharma Stock a Safer Way to Bet on Revolution Medicines?aol.com · 25 Sep 2026
Everyone who traded it
Same industry
Government contracts
Awards1
Total$15K
Latest9 Oct 2026
From its SEC filings
Analyst forecasts
No analyst forecasts yet.